Pneumagen presents positive phase 2 influenza human challenge study data on neumifil, its broad-spectrum antiviral drug, at the american thoracic society (ats) 2024 conference

St andrews, uk – 23nd may 2024 - pneumagen, a clinical stage biotech company developing neumifil (hex17), a broad-spectrum antiviral, intranasal drug for the prophylaxis and treatment of viral respiratory tract infections (rtis), presented positive results from its phase 2, proof-of-concept, controlled human infection model (chim) study in which healthy volunteers were challenged with influenza virus following administration of neumifil. these data were featured during an oral presentation* at the american thoracic society (ats) in san diego on 21st may.
ATS Ratings Summary
ATS Quant Ranking